Ionis Pharmaceuticals Inc. (IONS)

58.03
NASDAQ : Health Technology
Prev Close 57.60
Day Low/High 56.44 / 58.13
52 Wk Low/High 39.07 / 59.81
Avg Volume 928.50K
Exchange NASDAQ
Shares Outstanding 137.57M
Market Cap 7.92B
EPS 0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACIW, AEYE, HTA, IONS Downgrades: BCBP, DWSN, JAX, KORS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

First-in-class Therapies Using Advanced Antisense Chemistries Highlighted At 2018 American Society Of Hematology Annual Meeting

First-in-class Therapies Using Advanced Antisense Chemistries Highlighted At 2018 American Society Of Hematology Annual Meeting

Wholly-owned LICA drug for beta-thalassemia, IONIS-TMPRSS6-L Rx, demonstrates therapeutic potential with positive modulation of important disease-related biomarkers and increase of serum hepcidin in initial clinical study

Ionis Pharmaceuticals To Host Investor Day

Ionis Pharmaceuticals To Host Investor Day

Webcast on Friday, December 7 at 7:30 a.m. ET at www.ionispharma.com

Ionis Pharmaceuticals To Present At Upcoming Investor Conferences

Ionis Pharmaceuticals To Present At Upcoming Investor Conferences

CARLSBAD, Calif., Nov.

Ionis Reports Third Quarter 2018 Financial Results

Ionis Reports Third Quarter 2018 Financial Results

Year-to-date revenues increased more than 15% compared to 2017, driven by increased SPINRAZA revenue

Advances In Ionis' Novel Antisense Technology To Be Presented At 2018 Society For Neuroscience Meeting

Advances In Ionis' Novel Antisense Technology To Be Presented At 2018 Society For Neuroscience Meeting

12 presentations highlighting latest data from Ionis' Neurodegenerative Program including first-in-class therapies for untreatable diseases such as Alzheimer's, ALS, Alexander, and spinocerebellar ataxia type 3

Ionis Pharmaceuticals To Hold Third Quarter 2018 Financial Results Webcast

Ionis Pharmaceuticals To Hold Third Quarter 2018 Financial Results Webcast

Webcast scheduled for Tuesday, November 6th at 11:30 a.m. Eastern Time

Dr. C. Frank Bennett Receives Leslie Gehry Brenner Prize For Innovation In Science

Dr. C. Frank Bennett Receives Leslie Gehry Brenner Prize For Innovation In Science

Prestigious award recognizes the potential of Ionis' antisense technology to transform neurodegenerative disease

Phase 1b/2 Data Of Durvalumab Plus Danvatirsen Presented At European Society For Medical Oncology

Phase 1b/2 Data Of Durvalumab Plus Danvatirsen Presented At European Society For Medical Oncology

Response rate approximately doubled compared to previous studies with durvalumab alone in refractory head and neck cancer

Ionis Enters New Collaboration With Partner To Develop IONIS-FB-L Rx For Complement-Mediated Diseases

Ionis Enters New Collaboration With Partner To Develop IONIS-FB-L Rx For Complement-Mediated Diseases

Transaction valued at up to $760 million, including $75 million upfront payment, plus royalties up to 20%

Ionis Announces The Appointment Of Two New Board Members

Ionis Announces The Appointment Of Two New Board Members

CARLSBAD, Calif., Sept.

Ionis Pharmaceuticals To Present At Upcoming Investor Conferences

Ionis Pharmaceuticals To Present At Upcoming Investor Conferences

CARLSBAD, Calif., Aug.

Ionis Reports Second Quarter 2018 Financial Results

Ionis Reports Second Quarter 2018 Financial Results

Year-to-date revenues increased 15%, driven by increased SPINRAZA revenue

IONIS-HTT Rx (RG6042) Granted PRIME Designation By The European Medicines Agency For The Treatment Of People With Huntington's Disease

IONIS-HTT Rx (RG6042) Granted PRIME Designation By The European Medicines Agency For The Treatment Of People With Huntington's Disease

IONIS-HTT Rx is the first and only drug to demonstrate reduction of mutant huntingtin protein, the underlying cause of Huntington's disease, in patients

Akcea Therapeutics And PTC Therapeutics Collaborate To Commercialize Two Rare Disease Drugs In Latin America

Akcea Therapeutics And PTC Therapeutics Collaborate To Commercialize Two Rare Disease Drugs In Latin America

- PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea -

Interesting IONS Put And Call Options For September 21st

Interesting IONS Put And Call Options For September 21st

Investors in Ionis Pharmaceuticals Inc saw new options become available this week, for the September 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IONS options chain for the new September 21st contracts and identified one put and one call contract of particular interest.

Ionis Pharmaceuticals To Hold Second Quarter 2018 Financial Results Webcast

Ionis Pharmaceuticals To Hold Second Quarter 2018 Financial Results Webcast

Webcast scheduled for Tuesday, August 7th at 11:30 a.m. Eastern Time

Ionis Pharmaceuticals Larger Than S&P 500 Component Leggett & Platt

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ionis Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Leggett & Platt, Inc. , according to The Online Investor.

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Jim Cramer makes the calls on Alibaba, First American, Coherent, Ionis Pharmacuetical, Skechers USA, Corning, Bank of Internet and more.

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Love the banks, then hate the banks. Love the industrials? Nope, they're out, too. Jim Cramer says it's ugly, but he would use the weakness in the upside surprises.

Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological...

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

New Data Presented At MDA Clinical Conference Show Benefit In Motor Function For Infants, Teens And Young Adults Treated With SPINRAZA® (nusinersen)

Biogen (Nasdaq: BIIB) today announced new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA ® (nusinersen) among pre-symptomatic...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOG, FGEN, GASS, GHC, SATS Downgrades: ALB, CFBK, CLI, DISCB, FORM, HCCI, IONS, KOP, LTC, MNRO, PNTR, SRE Initiations: FRAC, JELD, REVG Read on to get TheStreet Quant Ratings' detailed report:

Biogen And Ionis Enter Into New Collaboration To Identify Novel Therapies For The Treatment Of Spinal Muscular Atrophy

Biogen And Ionis Enter Into New Collaboration To Identify Novel Therapies For The Treatment Of Spinal Muscular Atrophy

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of...

The New England Journal Of Medicine Publishes First Phase 3 Study Results Of SPINRAZA® For The Treatment Of Spinal Muscular Atrophy

The New England Journal Of Medicine Publishes First Phase 3 Study Results Of SPINRAZA® For The Treatment Of Spinal Muscular Atrophy

Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the end of study results from ENDEAR, the Phase 3 study of SPINRAZA ® (nusinersen) for the treatment of spinal muscular atrophy...

TheStreet Quant Rating: C- (Hold)